alendronate has been researched along with Stomach Neoplasms in 8 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 8.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Osteoporosis is found to have high prevalence after gastrectomy and therefore, it is important to prevent this condition by means of effective medication, such as alendronate sodium hydrate." | 5.24 | A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy. ( Akiyama, H; Endo, I; Izumisawa, Y; Kosaka, T; Kunisaki, C; Miyamoto, H; Sato, K; Sato, S; Suematsu, H; Taguri, M; Tanaka, Y; Yamanaka, T; Yukawa, N, 2017) |
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 4.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Osteoporosis and osteomalacia have been observed after gastrectomy and appear to be caused by reduced food intake and absorption, and steatorrhea." | 2.82 | Metabolic bone disorders after gastrectomy: inevitable or preventable? ( Aoyama, T; Atsumi, Y; Rino, Y; Yamada, T; Yukawa, N, 2022) |
| "Alendronate users had a lower risk of incident gastric cancer [odds ratio (OR) 0." | 1.38 | Esophageal and gastric cancer incidence and mortality in alendronate users. ( Abrahamsen, B; Eastell, R; Eiken, P; Pazianas, M; Russell, RG, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ha, J | 1 |
| Lee, JM | 1 |
| Lim, Y | 1 |
| Kim, MK | 1 |
| Kwon, HS | 1 |
| Song, KH | 1 |
| Jeon, HM | 1 |
| Kang, MI | 1 |
| Baek, KH | 1 |
| Rino, Y | 2 |
| Aoyama, T | 1 |
| Atsumi, Y | 2 |
| Yamada, T | 1 |
| Yukawa, N | 3 |
| Chen, LX | 1 |
| Ning, GZ | 1 |
| Zhou, ZR | 1 |
| Li, YL | 1 |
| Zhang, D | 1 |
| Wu, QL | 1 |
| Zhang, TS | 1 |
| Cheng, L | 1 |
| Feng, SQ | 1 |
| Wright, E | 1 |
| Schofield, PT | 1 |
| Molokhia, M | 1 |
| Sato, T | 1 |
| Cho, H | 1 |
| Yoshikawa, T | 1 |
| Yamamoto, N | 1 |
| Oshima, T | 1 |
| Shiozawa, M | 1 |
| Morinaga, S | 1 |
| Masuda, M | 1 |
| Kunisaki, C | 1 |
| Tanaka, Y | 1 |
| Kosaka, T | 1 |
| Miyamoto, H | 1 |
| Sato, S | 1 |
| Suematsu, H | 1 |
| Sato, K | 1 |
| Izumisawa, Y | 1 |
| Akiyama, H | 1 |
| Taguri, M | 1 |
| Yamanaka, T | 1 |
| Endo, I | 1 |
| Abrahamsen, B | 1 |
| Pazianas, M | 1 |
| Eiken, P | 1 |
| Russell, RG | 1 |
| Eastell, R | 1 |
| Weinreich, J | 1 |
| Schott, TC | 1 |
| Königsrainer, I | 1 |
| Küper, M | 1 |
| Königsrainer, A | 1 |
| Schott, H | 1 |
3 reviews available for alendronate and Stomach Neoplasms
| Article | Year |
|---|---|
Metabolic bone disorders after gastrectomy: inevitable or preventable?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; F | 2022 |
The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Colorectal Neoplasms; Female; Humans; | 2015 |
Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Esophageal Neoplasms; Humans; Stomach | 2015 |
2 trials available for alendronate and Stomach Neoplasms
| Article | Year |
|---|---|
Effect of bisphosphonate on the prevention of bone loss in patients with gastric cancer after gastrectomy: A randomized controlled trial.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Fe | 2020 |
A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservati | 2017 |
3 other studies available for alendronate and Stomach Neoplasms
| Article | Year |
|---|---|
Effectiveness of alendronate for bone disorder after gastrectomy for gastric cancer.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Cholecalciferol; | 2017 |
Esophageal and gastric cancer incidence and mortality in alendronate users.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Denmark; Esophageal Neoplasms; Etidronic | 2012 |
Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.
Topics: Adenocarcinoma; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line, | 2012 |